Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy ...

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Zymo’s Quick DNA/RNA Viral MagBead Kit was automated using Analytik Jena’s Cybio FeliX pipetting robot. The CyBio FeliX ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "North America RNA Therapeutics Market, By Country, Competition, Forecast & ...

Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have made a major discovery in how human ...